Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many mechanistic and monitoring statements are supported by the provided label sections, but several jaundice-related claims (incidence, seriousness/rarity characterization, subgroup associations, mechanism, and emergency-action wording) are not supported by the supplied label text, reducing overall alignment.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
11 DESCRIPTION and 12.1 Mechanism of Action (HMG-CoA reductase inhibitor; cholesterol biosynthesis inhibitor consistent with statin)
Lipitor works by reducing low-density lipoprotein (LDL) cholesterol in the blood.
12.1 Mechanism of Action (reduces LDL-C)
Lipitor inhibits HMG-CoA reductase, an enzyme involved in cholesterol synthesis.
11 DESCRIPTION and 12.1 Mechanism of Action (selective inhibitor of HMG-CoA reductase; conversion of HMG-CoA to mevalonate)
Yellowing skin (jaundice) is a potential side effect of Lipitor.
5.2 Liver Dysfunction (one patient developed jaundice)
Other potential side effects of Lipitor include muscle pain and weakness.
5.1 Skeletal Muscle (myopathy defined as muscle aches or muscle weakness; report muscle pain/tenderness/weakness)
Other potential side effects of Lipitor include diarrhea.
6.1 Clinical Trial Adverse Experiences (diarrhea listed; also in Table 2)
It is essential to monitor liver function while taking Lipitor.
5.2 Liver Dysfunction (perform liver function tests prior to and at 12 weeks after initiation and dose increases; periodically thereafter)
Regular blood tests can help identify changes in liver enzymes while taking Lipitor.
5.2 Liver Dysfunction and 17.2 Liver Enzymes (recommended liver function tests; monitoring until abnormalities resolve)
Unsupported Statements
Jaundice occurs in less than 1% of patients taking Lipitor.
The provided label text does not give a jaundice incidence percentage; 5.2 states one patient developed jaundice without a rate.
Yellowing skin on Lipitor is particularly associated with patients with pre-existing liver disease.
The provided label text supports caution in patients with history of liver disease and contraindications for active liver disease, but does not specifically associate jaundice with the pre-existing liver disease subgroup.
Yellowing skin on Lipitor is particularly associated with patients taking other medications that can affect the liver.
The provided label text discusses liver dysfunction and monitoring but does not specifically link jaundice to concomitant hepatotoxic medications.
The exact mechanism of yellowing skin on Lipitor is not fully understood.
No mechanistic discussion of jaundice (including 'not fully understood') is present in the provided label sections.
Yellowing skin on Lipitor is believed to be related to Lipitor's impact on the liver.
The label indicates liver function abnormalities and reports jaundice, but the provided text does not present a stated belief/mechanistic causal explanation.
When the liver is damaged or inflamed, it cannot process bilirubin properly.
No label text in the provided sections addresses bilirubin processing.
Bilirubin builds up in the blood when the liver cannot process bilirubin properly and causes the skin to turn yellow.
No label text provided discusses bilirubin buildup as the causal mechanism.
If a patient experiences yellowing skin on Lipitor, they should seek medical attention immediately.
The provided label text includes monitoring recommendations and dose reduction/withdrawal guidance, but does not provide an explicit 'seek medical attention immediately' instruction for jaundice.
Symptoms of liver damage on Lipitor can include dark urine, pale stools, and abdominal pain.
Those specific symptom examples are not provided in the supplied label sections.
Contradictions
Important Omissions
The evaluation did not cover other label safety/contraindication content (e.g., pregnancy/lactation, boxed warnings, full contraindication list beyond the provided liver disease text) because the supplied claim set did not include those topics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported jaundice incidence/seriousness characterization, subgroup association statements, mechanistic bilirubin claims, and lack of label-supported emergency escalation wording could misinform risk perception or action; other supported claims (mechanism, monitoring, common GI and muscle-related adverse reactions) partially mitigate impact.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several jaundice-related and mechanism/emergency-action claims are not supported by the provided label sections.
Suggested Improvement
Remove or rephrase unsupported jaundice claims (incidence <1%, 'rare but serious', specific subgroup associations, mechanism/bilirubin explanations, emergency-action wording, and specific alternative symptoms) unless corresponding FDA label text is provided; retain statements that are directly supported (HMG-CoA reductase inhibition, LDL-C reduction, liver function test monitoring, and label-listed adverse reactions such as diarrhea and nausea).